Clinical trial
Study of Etanercept in the Treatment of Psoriasis in Adult Subjects
NCT00121615 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00121615 |
|---|---|
| Title | Study of Etanercept in the Treatment of Psoriasis in Adult Subjects |
| Official title | An Open-Label, Long-Term Extension Study to Assess the Safety and Efficacy of Etanercept in the Treatment of Psoriasis in Adult Subjects |
| Lead sponsor | Amgen, Industry |
| Collaborators | Wyeth is now a wholly owned subsidiary of Pfizer Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Inflammation, Psoriasis |
| Intervention type | Drug |
| Interventions | etanercept |
| Enrollment | 391 |
| Start date | Oct 1, 2004 |
| First posted | Jul 21, 2005 |
| Last update posted | Mar 6, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: